表紙
市場調査レポート

MediPoint:神経血管インターベンション−−世界市場の分析と予測

MediPoint: Neurovascular Interventions - Global Analysis and Market Forecasts

発行 GlobalData 商品コード 298829
出版日 ページ情報 英文 432 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
MediPoint:神経血管インターベンション−−世界市場の分析と予測 MediPoint: Neurovascular Interventions - Global Analysis and Market Forecasts
出版日: 2014年04月02日 ページ情報: 英文 432 Pages
概要

世界の神経血管インターベンションは巨大で、2桁台の急速な速度で成長しています。神経インターベンション技術や低侵襲性治療技術の急速な進歩により、将来的に治療可能となる疾患の分野が広がりつつあります。神経血管インターベンションの市場は、血管閉塞・血管再生・機械的血栓除去・アクセス/サポートの4つの分野に分かれています。

当レポートでは、全世界の脳血管疾患(頭蓋内動脈瘤/動静脈奇形、アテローム性動脈硬化など)治療用の神経血管インターベンション市場について分析し、疾患の概要や市場構造、現在のアンメットニーズ、主な市場促進・抑制要因、今後の市場機会、現在治験中の主要製品、世界全体および主要10ヶ国における市場動向(過去3年間の実績値と今後7年間の予測値)、製品カテゴリー別の詳細動向、主要企業のプロファイルなどを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 臨床転帰

  • 疾患の管理
    • 頭蓋内動脈瘤
    • 頭蓋内動静脈奇形
    • 硬膜動静脈瘻
    • 頭蓋内/頭蓋外アテローム性動脈硬化
    • 脳卒中
  • 治療方式
    • 概要
    • 医薬/化学療法
    • 外科療法
    • 血管内療法

第4章 産業の概要

  • 概況
  • 処置の傾向
    • 頭蓋内動脈瘤
    • 頭蓋内動静脈奇形
    • アテローム性動脈硬化
    • 急性虚血発作
  • 市場へのアクセス
    • 規制のプロセス
    • 医師の認識・意思決定プロセス
    • 臨床診療のバリエーション
    • 臨床データの不足
    • 地域レベルでの管理
    • コストの考慮
    • 医療費償還の傾向
  • 規制上の課題/リコール
  • 企業合併・買収(M&A)/主なパートナーシップ(計11件)
  • 経済的な影響
    • 頭蓋内動脈瘤/動静脈奇形の場合
    • 脳卒中の場合
    • 脳血管疾患の治療費

第5章 アンメットニーズ

  • 概要
  • 訓練・実績・医師向け訓練ガイドラインのニーズ
  • 臨床データの不足
  • 急性虚血発作の管理の改善
  • 外科療法の複雑化への対処
  • クリッピング術の課題への対処
  • 未破裂頭蓋内動脈瘤の最適な治療戦略の欠如
  • 複雑な形態・規模の動脈瘤に対する効果的な治療法の必要性
  • 頭蓋内動静脈奇形の治療の難しさ
  • バルーン血管形成法に関する課題への対処
  • 神経血管ステントに関する課題への対処
  • 二重抗血小板療法(DAPT)の複雑化
  • 医薬療法の改善の必要性
  • アクセス緩和の必要性

第6章 市場機会の分析

  • 神経血管インターベンション市場
  • 神経インターベンション装置の設計改善
  • 複雑な頭蓋内動脈瘤/動静脈奇形の治療に関する課題
  • 多数の患者を対象とした治療法
  • 急性虚血発作の患者の治療法の最適化
  • 薬剤溶出デバイスの開発
  • 新興市場

第7章 市場促進要因と課題

  • 市場促進要因
    • 疾患の有病率の上昇
    • 血管内コイルによる臨床転帰の改善
    • ステント/バルーン支援下コイリングによる治療法の改変
    • 複雑頭蓋内動脈瘤の実行可能な治療オプション
    • 動脈瘤治療のための、コイル以外の代替的な閉塞形成装置
    • 頭蓋内動静脈奇形における血管内閉塞
    • 頭蓋内動静脈奇形治療のための画像診断
    • 頸動脈硬化性疾患のためのステント
    • 低プロファイルのステント装置
    • 機械的血栓除去装置の最疎通率の改善
    • コスト抑制
    • 長期的・コスト効率的なデータ入手の可能性
  • 市場の課題
    • 神経インターベンション処置・装置の複雑性
    • 臨床データの不足
    • 治療費の高さ
    • 医療費償還額の不足
    • 生理活性/被覆コイルの優位性の欠如
    • 脳卒中治療の代替的方法
    • 規制上の問題:米国FDAとECマーク
    • 医療費抑制の動きと医療費償還
    • ベンチャーキャピタルの利用可能性
    • 医療機器への物品税

第8章 競争力の評価

  • 概要
  • 世界市場シェア
  • 上市済み製品(計29製品)

第9章 パイプライン製品の評価

  • 概要
  • 開発段階別のパイプライン製品
  • 製品のプロファイル(計12製品)

第10章 治験の分析

  • 概要
  • 注目すべき治験
    • 血管閉塞
    • 血流迂回
    • 血管再生
    • 機械的血栓除去

第11章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル(計30社分)

第12章 市場の将来展望

  • 部門別の見通し
    • 血管閉塞装置の市場
    • 血管再生装置の市場
    • 機械的血栓除去装置の市場
    • アクセス/サポート用装置の市場
  • 地域別の見通し
    • 全体的状況
    • 米国
    • 欧州主要5ヶ国
    • 南米

第13章 付録

図表一覧

目次
Product Code: GDME0194MAR

The global neurovascular interventions market is a vast, double-digit market that consists of innovative and emerging technologies. Rapid advances in the field of neurovascular interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices.

Embolization devices including bare metal and bioactive/coated coils, aneurysm remodeling devices (stents and occlusion balloons), flow diversion devices and liquid embolic agents can be used to treat intracranial aneurysms and arteriovenous malformations (AVMs) and optimize outcomes. Low-profile stent and balloon systems can be used to revascularize plaque burdened arteries in the cerebrovasculature. Mechanical thrombectomy devices including distal and proximal devices and stent retrievers can improve recanalization rates and provide predictable outcomes in the setting of acute ischemic stroke (AIS). In addition, the next generation of access/support devices has been developed to improve navigation, trackability and flexibility as well as provide stable access, especially through tortuous anatomy.

This report focuses on the global neurovascular interventions market in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, China, India, and Brazil) for treating cerebrovascular disease including intracranial aneurysms and AVMs, atherosclerotic disease, and AIS. The global neurovascular interventions market is determined for the 10 countries covered in this report and provides insight into the competitive landscape, the marketed and pipeline products, the current and emerging players and market analysis of the different device segments within the neurointerventional market. The report identifies the unmet needs in the market while providing an understanding of physicians' perceptions and decision-making processes in using neurointerventional devices; this report also evaluates the adoption of various neurointerventional devices in the future.

Highlights

Key Questions Answered

  • The neurovascular interventions market is expected to continue its growth through the forecast period. (Q).What are the primary patient segments, indications and different product offerings in the neurovascular interventions market?
  • Endovascular therapy for cerebrovascular applications has seen rapid development in materials research and new techniques for treatment. (Q).What specific technologies/device segments will drive the market ? (Q).What are the future trends and drivers for growth in the market?
  • Innovative technologies such as flow diverters and stent retrievers have been developed to treat challenging indications. (Q).Is flow diversion a viable alternative for patients with complex aneurysms? (Q).Will stent retrievers continue to be adopted widely in clinical practice in the future? (Q).Do we see pricing pressure in the neurointerventional devices?
  • Stenting and balloon angioplasty is primarily performed in the setting of carotid artery stenosis. (Q).What is the market potential for revascularization devices? (Q).What is the market outlook for endovascular stenting for atherosclerotic disease?
  • The top players in this market have developed a broad and comprehensive portfolio of neurointerventional devices for various cerebrovascular indications. (Q).What role do smaller players have in grabbing market share in the different global regions? (Q).Who are the key players in the neurovascular interventional market?

Scope

  • Overview of cerebrovascular disease, including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.
  • Annualized total neurovascular interventions market revenue by device segment, annual cost of disease and neurointerventional devices adoption pattern and procedure data from 2011-2013 and forecast for seven years to 2020.
  • Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in each region covered in the report, and implications of the neurovascular interventions market.
  • Pipeline analysis: Comprehensive data split across different stages of development, emerging trends and device designs in development.
  • Analysis of the current and future market competition in the global neurovascular interventions market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global neurovascular interventions market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neurovascular interventions market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific neurovascular interventions market from 2011-2020.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Clinical Outcomes

  • 3.1. Disease Management
    • 3.1.1. Intracranial Aneurysms
    • 3.1.2. Intracranial Arteriovenous Malformations
    • 3.1.3. Dural Arteriovenous Fistulas
    • 3.1.4. Intracranial and Extracranial Atherosclerotic Disease
    • 3.1.5. Stroke
  • 3.2. Treatment Modalities
    • 3.2.1. Overview
    • 3.2.2. Medical/Chemical Therapy
    • 3.2.3. Surgical Therapy
    • 3.2.4. Endovascular Therapy

4. Industry Overview

  • 4.1. Overview
  • 4.2. Procedure Trends
    • 4.2.1. Intracranial Aneurysms
    • 4.2.2. Intracranial Arteriovenous Malformations
    • 4.2.3. Atherosclerotic Disease
    • 4.2.4. Acute Ischemic Stroke
  • 4.3. Market Access
    • 4.3.1. Regulatory Process
    • 4.3.2. Physician Perception and Decision Making Process
    • 4.3.3. Variations in Clinical Practice
    • 4.3.4. Lack of Clinical Data
    • 4.3.5. Regional-Level Control
    • 4.3.6. Cost-Considerations
    • 4.3.7. Reimbursement Trends
  • 4.4. Regulatory Issues/Recalls
    • 4.4.1. Regulatory Issues
    • 4.4.2. Product Recalls
  • 4.5. Mergers and Acquisitions/Key Partnerships
    • 4.5.1. Covidien and Nfocus Neuromedical
    • 4.5.2. Stryker Corporation and Surpass Medical
    • 4.5.3. Covidien and MindFrame
    • 4.5.4. Covidien and Reverse Medical Corporation
    • 4.5.5. Stryker Corporation and Boston Scientific Neurovascular
    • 4.5.6. Stryker Corporation and Concentric Medical
    • 4.5.7. Covidien and ev3
    • 4.5.8. Medtronic and Invatec
    • 4.5.9. Johnson & Johnson and Micrus Endovascular
    • 4.5.10. ev3 and Chestnut Medical Technologies
    • 4.5.11. Boston Scientific Corporation and Guidant Corporation
  • 4.6. Economic Impact
    • 4.6.1. Economic Impact of Intracranial Aneurysms and Arteriovenous Malformations
    • 4.6.2. Economic Impact of Stroke
    • 4.6.3. Treatment Costs of Cerebrovascular Disease

5. Unmet Needs

  • 5.1. Overview
  • 5.2. Need for Practice, Performance, and Physician Training Guidelines
  • 5.3. Lack of Clinical Data
  • 5.4. Improve Management of Acute Ischemic Stroke
  • 5.5. Address Complications of Surgical Therapy
  • 5.6. Addressing the Challenges of Surgical Clipping
  • 5.7. Lack of Optimal Treatment Strategy for Unruptured Intracranial Aneurysms
  • 5.8. Need for Effective Therapies for Complex Aneurysm Morphologies and Sizes
  • 5.9. Difficulty in Treating Intracranial Arteriovenous Malformations
  • 5.10. Eliminating Mechanisms of Failure with Balloon Angioplasty
  • 5.11. Addressing Challenges of Neurovascular Stenting
    • 5.11.1. Risk of Post-Procedural Complications
    • 5.11.2. In-Stent Restenosis
    • 5.11.3. Stent Navigation
  • 5.12. Complications of Dual Antiplatelet Therapy
  • 5.13. Need to Improve Medical Therapy
  • 5.14. Improve Ease of Access

6. Market Opportunity Analysis

  • 6.1. Neurovascular Interventions Market
  • 6.2. Improve Neurointerventional Device Design
  • 6.3. Challenges in Treating Complex Intracranial Aneurysms and Arteriovenous Malformations
    • 6.3.1. Intracranial Aneurysms
    • 6.3.2. Intracranial Arteriovenous Malformations
  • 6.4. Target Challenging Patient Populations
  • 6.5. Optimize Care for Acute Ischemic Stroke Patients
  • 6.6. Development of Drug-Eluting Devices
  • 6.7. Emerging Markets

7. Market Drivers and Barriers

  • 7.1. Market Drivers
    • 7.1.1. Rising Prevalence of Disease
    • 7.1.2. Improved Clinical Outcomes with Endovascular Coiling
    • 7.1.3. Remodeling Techniques with Stent and Balloon-Assisted Coiling
    • 7.1.4. Viable Therapeutic Option for Challenging/Complex Intracranial Aneurysms
    • 7.1.5. Alternative Non-Coiling Embolization Devices for Aneurysm Treatment
    • 7.1.6. Endovascular Embolization of Intracranial Arteriovenous Malformations
    • 7.1.7. Imaging Assessment for Intracranial Arteriovenous Malformation Treatment
    • 7.1.8. Stenting for Carotid Atherosclerotic Disease
    • 7.1.9. Low-Profile Stent Systems
    • 7.1.10. Improved Recanalization Rates with Mechanical Thrombectomy Devices
    • 7.1.11. Cost Savings
    • 7.1.12. Availability of Long-Term and Cost-Effective Data
  • 7.2. Market Barriers
    • 7.2.1. Complications of Neurointerventional Procedures and Devices
    • 7.2.2. Lack of Clinical Data
    • 7.2.3. High Cost of Treatment
    • 7.2.4. Lack of Reimbursement
    • 7.2.5. Lack of Superiority of Bioactive/Coated Coils
    • 7.2.6. Alternative Technologies for Stroke Therapy
    • 7.2.7. Regulatory Challenges: US Food and Drug Administration and European Conformity Mark
    • 7.2.8. Healthcare Cost-Cutting and Reimbursement
    • 7.2.9. Availability of Venture Capital
    • 7.2.10. Medical Device Excise Tax

8. Competitive Assessment

  • 8.1. Overview
  • 8.2. Global Market Share
  • 8.3. Marketed Products
    • 8.3.1. Aachen Resonance
    • 8.3.2. Abbott Vascular
    • 8.3.3. Acandis
    • 8.3.4. B. Braun
    • 8.3.5. BALT Extrusion
    • 8.3.6. Blockade Medical
    • 8.3.7. Boston Scientific Corporation
    • 8.3.8. Contego Medical
    • 8.3.9. Cook Medical
    • 8.3.10. Covidien
    • 8.3.11. Gardia Medical
    • 8.3.12. Gore Medical
    • 8.3.13. InspireMD
    • 8.3.14. ITGI Medical
    • 8.3.15. Johnson & Johnson
    • 8.3.16. Medikit
    • 8.3.17. Medtronic
    • 8.3.18. Merlin MD
    • 8.3.19. MicroPort Scientific Corporation
    • 8.3.20. Minvasys
    • 8.3.21. Neuravi
    • 8.3.22. Optimed
    • 8.3.23. Penumbra
    • 8.3.24. Phenox GmbH
    • 8.3.25. Reverse Medical
    • 8.3.26. Sequent Medical
    • 8.3.27. Stryker Neurovascular Intervention
    • 8.3.28. Terumo Corporation
    • 8.3.29. Valor Medical

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Pipeline by Stage of Development
  • 9.3. Product Profiles
    • 9.3.1. Aneurysm Occlusion Saddle
    • 9.3.2. Ballstent Microcatheter
    • 9.3.3. Blood Clot Removing Device
    • 9.3.4. EKOS' EkoSonic Small Vessel Endovascular System
    • 9.3.5. Flow-Diverting Thin-Film Nitinol Covered Stent
    • 9.3.6. Ischemic Stroke System
    • 9.3.7. Janjua Aneurysm Net
    • 9.3.8. Multilayer Aneurysm Repair System
    • 9.3.9. NAVIMAX
    • 9.3.10. Palmaz Scientific Stents
    • 9.3.11. Silk Road System
    • 9.3.12. Transcranial Thrombectomy Catheter

10. Clinical Trial Analysis

  • 10.1. Overview
  • 10.2. Clinical Trials to Watch
    • 10.2.1. Embolization
    • 10.2.2. Flow Diversion
    • 10.2.3. Revascularization
    • 10.2.4. Mechanical Thrombectomy

11. Current and Future Players

  • 11.1. Overview
  • 11.2. Trends in Corporate Strategy
  • 11.3. Company Profiles
    • 11.3.1. BALT Extrusion
    • 11.3.2. Covidien
    • 11.3.3. Johnson & Johnson
    • 11.3.4. Penumbra
    • 11.3.5. Stryker Corporation
    • 11.3.6. Terumo Corporation
    • 11.3.7. Abbott Vascular
    • 11.3.8. Boston Scientific Corporation
    • 11.3.9. Cook Medical
    • 11.3.10. Gore Medical
    • 11.3.11. Medtronic
    • 11.3.12. Aachen Resonance
    • 11.3.13. Acandis
    • 11.3.14. B. Braun
    • 11.3.15. Blockade Medical
    • 11.3.16. Contego Medical
    • 11.3.17. Gardia Medical
    • 11.3.18. InspireMD
    • 11.3.19. ITGI Medical
    • 11.3.20. Medikit
    • 11.3.21. Merlin MD
    • 11.3.22. MicroPort Scientific Corporation
    • 11.3.23. Minvasys
    • 11.3.24. Neuravi
    • 11.3.25. Optimed
    • 11.3.26. Phenox GmBH
    • 11.3.27. Reverse Medical
    • 11.3.28. Sequent Medical
    • 11.3.29. Valor Medical
    • 11.3.30. Other Companies

12. Market Outlooks

  • 12.1. By Market Segment
    • 12.1.1. Embolization Device Market
    • 12.1.2. Revascularization Device Market
    • 12.1.3. Mechanical Thrombectomy Device Market
    • 12.1.4. Access/Support Device Market
  • 12.2. By Geography
    • 12.2.1. Global Overview
    • 12.2.2. United States
    • 12.2.3. The Five European Union Markets
    • 12.2.4. The Asia-Pacific Region
    • 12.2.5. South America

13. Appendix

  • 13.1. Bibliography
  • 13.2. Abbreviations
  • 13.3. Report Methodology
    • 13.3.1. Overview
    • 13.3.2. Coverage
    • 13.3.3. Secondary Research
  • 13.4. Physicians and Specialists Included in this Study
    • 13.4.1. Vivek Gupta, MD
    • 13.4.2. Zsolt Kulscar, MD, PhD
    • 13.4.3. Salvatore Mangiafico, MD
    • 13.4.4. Thanh Nguyen, MD, FRCPc
    • 13.4.5. Eduardo Wajnberg, MD
    • 13.4.6. Phil White, MD
    • 13.4.7. Osama O Zaidat, MD, MS, FAAN, FAHA
  • 13.5. Primary Research
    • 13.5.1. Primary Research - Key Opinion Leader Interviews
    • 13.5.2. Expert Panel Validation
  • 13.6. Forecasting Methodology
  • 13.7. About the Authors
    • 13.7.1. Analysts
    • 13.7.2. Global Head of Healthcare
  • 13.8. About MediPoint
  • 13.9. About GlobalData
  • 13.10. Disclaimer

List of Tables

  • Table 1: Complications of Cerebral Artery Bypass Surgery
  • Table 2: Types of Cerebral Embolic Protection Devices
  • Table 3: Medicare National Average of Inpatient Hospital Payment for Neurovascular Interventions, 2013-2014
  • Table 4: Reimbursement Classification of Medical Devices in Japan
  • Table 5: US Mean Hospital Costs* for Treating Cerebrovascular Disease, 2011-2020 ($US)
  • Table 6: Aachen Resonance Neurovascular Intervention Marketed Product
  • Table 7: Aachen Resonance Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 8: Abbott Vascular Neurovascular Intervention Marketed Products
  • Table 9: Abbott Vascular Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 10: Acandis Neurovascular Intervention Marketed Products
  • Table 11: Acandis Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 12: B. Braun Neurovascular Intervention Marketed Product
  • Table 13: B. Braun Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 14: BALT Extrusion Neurovascular Intervention Marketed Products
  • Table 15: BALT Extrusion Neurovascular Intervention Marketed Access Products
  • Table 16: BALT Extrusion Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 17: Blockade Medical Neurovascular Intervention Marketed Product
  • Table 18: Blockade Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 19: Boston Scientific Neurovascular Intervention Marketed Products
  • Table 20: Boston Scientific Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 21: Contego Medical Neurovascular Intervention Marketed Product
  • Table 22: Contego Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 23: Cook Medical Neurovascular Intervention Marketed Products
  • Table 24: Cook Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 25: Covidien Neurovascular Interventional Marketed Products
  • Table 26: Covidien Neurovascular Intervention Marketed Access Products
  • Table 27: Covidien Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 28: Gardia Medical Neurovascular Intervention Marketed Product
  • Table 29: Gardia Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 30: Gore Medical Neurovascular Intervention Marketed Products
  • Table 31: Gore Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 32: InspireMD Neurovascular Intervention Marketed Product
  • Table 33: InspireMD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 34: ITGI Medical Neurovascular Intervention Marketed Product
  • Table 35: ITGI Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 36: Codman Neurovascular Marketed Embolization Products
  • Table 37: Codman Neurovascular Marketed Mechanical Thrombectomy and Access Products
  • Table 38: Codman Neurovascular's (Codman & Shurtleff) Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 39: Cordis Corporation Marketed Neurointerventional Products
  • Table 40: Cordis Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 41: Medikit Neurovascular Intervention Marketed Products
  • Table 42: Medikit Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 43: Medtronic Neurovascular Intervention Marketed Products
  • Table 44: Medtronic Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 45: Merlin MD Neurovascular Intervention Marketed Product
  • Table 46: Merlin MD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 47: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products
  • Table 48: MicroPort Scientific Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 49: Minvasys Neurovascular Intervention Marketed Product
  • Table 50: Minvasys Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 51: Neuravi Neurovascular Intervention Marketed Product
  • Table 52: Neuravi Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 53: Optimed Neurovascular Intervention Marketed Products
  • Table 54: Optimed Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 55: Penumbra Neurovascular Intervention Marketed Products
  • Table 56: Penumbra Marketed Neurovascular Access Products
  • Table 57: Penumbra Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 58: Phenox GmbH Neurovascular Intervention Marketed Products
  • Table 59: Phenox GmbH Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 60: Reverse Medical Neurovascular Intervention Marketed Products
  • Table 61: Reverse Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 62: Sequent Medical Neurovascular Intervention Marketed Products
  • Table 63: Sequent Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 64: Stryker Neurovascular Intervention Marketed Products
  • Table 65: Stryker Neurovascular Intervention Marketed Mechanical Thrombectomy and Access Products
  • Table 66: Stryker Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 67: Terumo Europe N.V. and Terumo Interventional Systems Marketed Neurointerventional Products
  • Table 68: Terumo Corporation Neurovascular Product Portfolio SWOT Analysis, 2014
  • Table 69: MicroVention Neurovascular Intervention Marketed Products
  • Table 70: MicroVention Marketed Neurovascular Access Products
  • Table 71: MicroVention Neurovascular Product Portfolio SWOT Analysis, 2014
  • Table 72: Valor Medical Neurovascular Intervention Marketed Products
  • Table 73: Valor Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 74: Global Neurovascular Interventions Pipeline Products
  • Table 75: Aneurysm Occlusion Saddle SWOT Analysis, 2014
  • Table 76: EKOS EkoSonic SV System SWOT Analysis, 2014
  • Table 77: Flow-Diverting Thin-Film Nitinol Covered Stent SWOT Analysis, 2014
  • Table 78: Janjua Aneurysm Net SWOT Analysis, 2014
  • Table 79: Multilayer Aneurysm Repair System SWOT Analysis, 2014
  • Table 80: NAVIMAX SWOT Analysis, 2014
  • Table 81: Palmaz Scientific Stents SWOT Analysis, 2014
  • Table 82: Silk Road System SWOT Analysis, 2014
  • Table 83: BALT Extrusion Company Profile
  • Table 84: BALT Extrusion Neurovascular Intervention Marketed Products
  • Table 85: BALT Extrusion SWOT Analysis, 2014
  • Table 86: Covidien Company Profile
  • Table 87: Covidien Neurovascular Intervention Marketed Products
  • Table 88: Covidien SWOT Analysis, 2014
  • Table 89: Codman & Shurtleff Company Profile
  • Table 90: Codman & Shurtleff Neurovascular Intervention Marketed Products
  • Table 91: Codman & Shurtleff SWOT Analysis, 2014
  • Table 92: Cordis Corporation Company Profile
  • Table 93: Cordis Corporation Neurovascular Intervention Marketed Products
  • Table 94: Cordis Corporation SWOT Analysis, 2014
  • Table 95: Penumbra Company Profile
  • Table 96: Penumbra Neurovascular Intervention Marketed Products
  • Table 97: Penumbra SWOT Analysis, 2014
  • Table 98: Stryker Corporation Company Profile
  • Table 99: Stryker Corporation Neurovascular Intervention Marketed Products
  • Table 100: Stryker Corporation SWOT Analysis, 2014
  • Table 101: Terumo Corporation Company Profile
  • Table 102: Terumo Europe N.V. and Terumo Interventional Systems Neurovascular Intervention Marketed Products
  • Table 103: MicroVention Neurovascular Intervention Marketed Products
  • Table 104: Terumo Corporation SWOT Analysis, 2014
  • Table 105: Abbott Vascular Company Profile
  • Table 106: Abbott Vascular Neurovascular Intervention Marketed Products
  • Table 107: Abbott Vascular SWOT Analysis, 2014
  • Table 108: Boston Scientific Corporation Company Profile
  • Table 109: Boston Scientific Neurovascular Intervention Marketed Products
  • Table 110: Boston Scientific Corporation SWOT Analysis, 2014
  • Table 111: Cook Medical Company Profile
  • Table 112: Cook Medical Neurovascular Intervention Marketed Products
  • Table 113: Cook Medical SWOT Analysis, 2014
  • Table 114: Gore Medical Company Profile
  • Table 115: Gore Medical Neurovascular Intervention Marketed Products
  • Table 116: Gore Medical SWOT Analysis, 2014
  • Table 117: Medtronic Company Profile
  • Table 118: Medtronic Neurovascular Intervention Marketed Products
  • Table 119: Medtronic SWOT Analysis, 2014
  • Table 120: Aachen Resonance Company Profile
  • Table 121: Aachen Resonance Neurovascular Intervention Marketed Product
  • Table 122: Aachen Resonance SWOT Analysis, 2014
  • Table 123: Acandis Company Profile
  • Table 124: Acandis Neurovascular Intervention Marketed Products
  • Table 125: Acandis SWOT Analysis, 2014
  • Table 126: B. Braun Company Profile
  • Table 127: B. Braun Neurovascular Intervention Marketed Product
  • Table 128: B. Braun SWOT Analysis, 2014
  • Table 129: Blockade Medical Company Profile
  • Table 130: Blockade Medical Neurovascular Intervention Marketed Product
  • Table 131: Blockade Medical SWOT Analysis, 2014
  • Table 132: Contego Medical Company Profile
  • Table 133: Contego Medical Neurovascular Intervention Marketed Product
  • Table 134: Contego Medical SWOT Analysis, 2014
  • Table 135: Gardia Medical Company Profile
  • Table 136: Gardia Medical Neurovascular Intervention Marketed Product
  • Table 137: Gardia Medical SWOT Analysis, 2014
  • Table 138: InspireMD Company Profile
  • Table 139: InspireMD Neurovascular Intervention Marketed Product
  • Table 140: InspireMD SWOT Analysis, 2014
  • Table 141: ITGI Medical Company Profile
  • Table 142: ITGI Medical Neurovascular Intervention Marketed Product
  • Table 143: ITGI Medical SWOT Analysis, 2014
  • Table 144: Medikit Company Profile
  • Table 145: Medikit Neurovascular Intervention Marketed Products
  • Table 146: Medikit SWOT Analysis, 2014
  • Table 147: Merlin MD Company Profile
  • Table 148: Merlin MD Neurovascular Intervention Marketed Product
  • Table 149: Merlin MD SWOT Analysis, 2014
  • Table 150: MicroPort Scientific Corporation Company Profile
  • Table 151: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products
  • Table 152: MicroPort Scientific Corporation SWOT Analysis, 2014
  • Table 153: Minvasys Company Profile
  • Table 154: Minvasys Neurovascular Intervention Marketed Product
  • Table 155: Minvasys SWOT Analysis, 2014
  • Table 156: Neuravi Company Profile
  • Table 157: Neuravi Neurovascular Intervention Marketed Product
  • Table 158: Neuravi SWOT Analysis, 2014
  • Table 159: Optimed Company Profile
  • Table 160: Optimed Neurovascular Intervention Marketed Products
  • Table 161: Optimed SWOT Analysis, 2014
  • Table 162: Phenox GmBH Company Profile
  • Table 163: Phenox GmbH Neurovascular Intervention Marketed Products
  • Table 164: Phenox GmBH SWOT Analysis, 2014
  • Table 165: Reverse Medical Company Profile
  • Table 166: Reverse Medical Neurovascular Intervention Marketed Products
  • Table 167: Reverse Medical SWOT Analysis, 2014
  • Table 168: Sequent Medical Company Profile
  • Table 169: Sequent Medical Neurovascular Intervention Marketed Products
  • Table 170: Sequent Medical SWOT Analysis, 2014
  • Table 171: Valor Medical Company Profile
  • Table 172: Valor Medical Neurovascular Intervention Marketed Products
  • Table 173: Valor Medical SWOT Analysis, 2014
  • Table 174: Other Companies in the Neurovascular Intervention Market, 2014
  • Table 175: Global Embolization Device Market ($m) Forecast, 2011-2020
  • Table 176: Global Revascularization Device Market ($m) Forecast, 2011-2020
  • Table 177: Global Mechanical Thrombectomy Device Market ($m) Forecast, 2011-2020
  • Table 178: Global Access/Support Device Market ($m) Forecast, 2011-2020
  • Table 179: Neurovascular Interventions Market Sales ($m) Forecast for the US, 2011-2020
  • Table 180: Neurovascular Interventions Market Sales ($m) Forecast for France, 2011-2020
  • Table 181: Neurovascular Interventions Market Sales ($m) Forecast for Germany, 2011-2020
  • Table 182: Neurovascular Interventions Market Sales ($m) Forecast for Italy, 2011-2020
  • Table 183: Neurovascular Interventions Market Sales ($m) Forecast for Spain, 2011-2020
  • Table 184: Neurovascular Interventions Market Sales ($m) Forecast for the UK, 2011-2020
  • Table 185: Neurovascular Interventions Market Sales ($m) Forecast for Japan, 2011-2020
  • Table 186: Neurovascular Interventions Market Sales ($m) Forecast for China, 2011-2020
  • Table 187: Neurovascular Interventions Market Sales ($m) Forecast for India, 2011-2020
  • Table 188: Neurovascular Interventions Market Sales ($m) Forecast for Brazil, 2011-2020

List of Figures

  • Figure 1: Treatment Modalities - Neurovascular Interventions
  • Figure 2: Types of Stents Used for Neurovascular Interventions
  • Figure 3: Embolization Procedure Volume for Treating Intracranial Aneurysms, US, 2011-2020
  • Figure 4: Embolization Procedure Volume for Treating Intracranial Aneurysms, 5EU, 2011-2020
  • Figure 5: Embolization Procedure Volume for Treating Intracranial Aneurysms, APAC, 2011-2020
  • Figure 6: Embolization Procedure Volume for Treating Intracranial Aneurysms, South America, 2011-2020
  • Figure 7: Embolization Procedure Volume for Treating Intracranial Arteriovenous Malformations, Global, 2011-2020
  • Figure 8: Revascularization Procedure Volume for Treating Atherosclerotic Disease, US, 2011-2020
  • Figure 9: Revascularization Procedure Volume for Treating Atherosclerotic Disease, 5EU, 2011-2020
  • Figure 10: Revascularization Procedure Volume for Treating Atherosclerotic Disease, APAC, 2011-2020
  • Figure 11: Revascularization Procedure Volume for Treating Atherosclerotic Disease, South America, 2011-2020
  • Figure 12: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, US, 2011-2020
  • Figure 13: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, 5EU, 2011-2020
  • Figure 14: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, APAC, 2011-2020
  • Figure 15: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, South America, 2011-2020
  • Figure 16: US Mean Hospital Costs* for Treating Intracranial Aneurysms and Arteriovenous Malformations, 2011-2020 ($US)
  • Figure 17: US Mean Hospital Costs* for Treating Extracranial and Intracranial Atherosclerotic Disease, 2011-2020 ($US)
  • Figure 18: US Mean Hospital Costs* for Treating Stroke, 2011-2020 ($US)
  • Figure 19: Global Neurointerventional Market Distribution, 2013
  • Figure 20: Global Neurovascular Interventions Pipeline Products by Stage of Development, 2014
  • Figure 21: Global Neurovascular Interventions Market ($bn) for Treating Cerebrovascular Disease, 2011-2020
  • Figure 22: Distribution of Percentage of Patients Treated for Cerebrovascular Disease, Global, 2013
  • Figure 23: Global Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 24: Global Embolization Device Market Distribution, 2013 and 2020
  • Figure 25: Global Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 26: Global Revascularization Device Market Distribution, 2013 and 2020
  • Figure 27: Global Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 28: Global Mechanical Thrombectomy Device Market Distribution, 2013 and 2020
  • Figure 29: Global Access/Support Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 30: Global Access/Support Device Market Distribution, 2013 and 2020
  • Figure 31: Global Neurovascular Interventions Market Revenue ($bn), 2013 and 2020
  • Figure 32: US Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 33: US Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 34: US Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 35: US Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 36: US Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 37: French Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 38: French Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 39: French Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 40: French Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 41: French Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 42: German Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 43: German Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 44: German Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 45: German Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 46: German Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 47: Italian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 48: Italian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 49: Italian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 50: Italian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 51: Italian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 52: Spanish Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 53: Spanish Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 54: Spanish Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 55: Spanish Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 56: Spanish Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 57: UK Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 58: UK Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 59: UK Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 60: UK Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 61: UK Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 62: Japanese Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 63: Japanese Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 64: Japanese Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 65: Japanese Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 66: Japanese Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 67: Chinese Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 68: Chinese Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 69: Chinese Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 70: Chinese Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 71: Chinese Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 72: Indian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 73: Indian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 74: Indian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 75: Indian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 76: Indian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 77: Brazilian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 78: Brazilian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 79: Brazilian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 80: Brazilian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 81: Brazilian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
Back to Top